Drug Profile
Espindolol - Actimed Therapeutics
Alternative Names: ACM 001; ACM-001.1; MT-102; S-pindolol; S-pindolol benzoateLatest Information Update: 04 Oct 2023
Price :
$50
*
At a glance
- Originator PsiOxus Therapeutics
- Developer Actimed Therapeutics; Akamis Bio
- Class Irritable bowel syndrome therapies; Small molecules
- Mechanism of Action 5-HT1A serotonin receptor antagonists; Beta-adrenergic receptor agonists; Beta-adrenergic receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase II Cachexia
- Discontinued Sarcopenia